FDA fast-tracks OTC drugs with thinner safety data—a speed-vs.-safety trade-off
H.R. 9774 — To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes. · Filed by Robert Latta (R-OH) · 1 cosponsor · Introduced Jul 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new expedited approval pathway for over-the-counter (nonprescription) drugs at the FDA. Drug manufacturers can request 'priority' status for new OTC drugs that address novel health conditions, are new chemical entities, or contain active ingredients never sold OTC before; the FDA must decide within 60 days and then provide accelerated review support including dedicated project leads and collaborative meetings. The bill does not lower safety or efficacy standards—drugs still must meet all existing approval requirements—but streamlines the review process. The FDA must publish a list of health conditions where OTC drugs could provide public benefit, and the program sunsets in 2032.
Why we flagged it
The bill's core mechanism is a new FDA designation and review process for nonprescription drugs, designed to accelerate time-to-market for novel OTC treatments while maintaining existing safety/efficacy standards. It is a regulatory streamlining measure, not a safety deregulation or industry carve-out.
What the text implies
- Reliance on 'real world evidence' in place of traditional clinical trials may lower the evidentiary bar for OTC approval, potentially allowing drugs to reach consumers with less rigorous safety/efficacy data than current practice.
- The 60-day designation decision window and expedited review may create pressure on FDA staff to approve drugs faster, potentially compromising thoroughness of safety review.
The full analysis lists 4 implications of this text.
Who stands to gain
OTC drug manufacturers; pharmaceutical companies seeking to convert prescription drugs to OTC status; contract research organizations (CROs) conducting real-world evidence studies